Novo Nordisk Launches Low-Priced Insulin In US
Introduces Authorized Generics Of Its NovoLog And NovoLog Mix
Novo Nordisk says it is offering solutions to the unaffordability and inaccessibility of insulin by launching US authorized generics of its NovoLog and NovoLog Mix brands. The originator is also introducing a ‘My$99Insulin’ plan and an ‘immediate supply’ option to “help people with diabetes who need alternative solutions.”
You may also be interested in...
Walmart, the famous American multinational retailer, has launched what it is billing as the “first and only” private brand analog insulin, under the company’s brand ReliOn, in partnership with Novo Nordisk. The firm is offering ReliOn NovoLog (insulin aspart) vials and FlexPen in its pharmacies immediately.
Biologics with their brand name dropped from the label could become the alternative to an ‘authorized biosimilar,’ which is not allowed under the law.
Exactly how many NDAs ultimately will make the switch, the impact of pending applications on 'Orange Book' listings, and the ramifications for ‘authorized generics’ are areas of focus as the regulatory transition date looms.